Keyphrases
Angiogenic
100%
Operative
100%
Proliferative Diabetic Retinopathy
100%
Short-term Effects
100%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
100%
Fibrovascular Membranes
100%
Endothelial Cells
83%
Intravitreal Bevacizumab
66%
Endothelin-1 (ET-1)
50%
Gene Expression
33%
Angiogenesis
33%
Vascular Endothelial Growth Factor
33%
Fibronectin
33%
Cellular Compartments
16%
Postoperative Bleeding
16%
Decreased Expression
16%
Vascular Endothelial Growth Factor Receptor (VEGFR)
16%
Quantitative PCR
16%
Profibrotic Genes
16%
CD31
16%
Off-target Effects
16%
Transcriptional Changes
16%
Myofibroblastic
16%
Vascular Integrity
16%
Intravitreal Anti-vascular Endothelial Growth Factor Injection
16%
Cell Integrity
16%
Flt-1
16%
Pars Plana Vitrectomy
16%
Relative Expression
16%
Cell Fraction
16%
Vascular Endothelial-cadherin
16%
Angiopoietin-2
16%
Pro-fibrotic Factors
16%
Microbeads
16%
QPCR Quantification
16%
Medicine and Dentistry
Endothelial Cell
100%
Vasculotropin
100%
Proliferative Diabetic Retinopathy
100%
Bevacizumab
80%
Angiogenesis
40%
Fibronectin
40%
Endothelin 1
40%
Gene Expression
20%
Quantitative Reverse Transcription Polymerase Chain Reaction
20%
Operative Blood Loss
20%
Vasculotropin Receptor
20%
Pars Plana Vitrectomy
20%
Vascular Endothelial Cadherin
20%
Angiopoietin 2
20%
Cell Compartment
20%
Endothelin
20%
Messenger RNA
20%